The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations

DE Berryman, CAM Glad, EO List… - Nature Reviews …, 2013 - nature.com
Obesity has become one of the most common medical problems in developed countries,
and this disorder is associated with high incidences of hypertension, dyslipidaemia …

Insulin-like growth factor-I (IGF-I) and clinical nutrition

C Livingstone - Clinical science, 2013 - portlandpress.com
IGF-I (insulin-like growth factor-I) is a peptide hormone, produced predominantly by the liver
in response to pituitary GH (growth hormone), which is involved in a wide variety of …

SIRT1 regulates adaptive response of the growth hormone--insulin-like growth factor-I axis under fasting conditions in liver

M Yamamoto, G Iguchi, H Fukuoka… - Proceedings of the …, 2013 - National Acad Sciences
Adaptation under fasting conditions is critical for survival in animals. Sirtuin 1 (SIRT1), a
protein deacetylase, plays an essential role in adaptive metabolic and endocrine responses …

Increased expression of fibroblast growth factor 21 (FGF21) during chronic undernutrition causes growth hormone insensitivity in chondrocytes by inducing leptin …

S Wu, T Grunwald, A Kharitonenkov, J Dam… - Journal of Biological …, 2013 - ASBMB
During calorie restriction in mice, increased expression of FGF21 causes growth attenuation
and growth hormone (GH) insensitivity. Previous evidence also indicates that fasting …

Determination of IGFs and their binding proteins

R Hjortebjerg, J Frystyk - Best Practice & Research Clinical Endocrinology & …, 2013 - Elsevier
The worldwide clinical and scientific interest in peptides belonging to the insulin-like growth
factor (IGF) system has brought along a call for standardization of assays used to quantify …

The role of combination medical therapy in acromegaly: hope for the nonresponsive patient

M Fleseriu - Current Opinion in Endocrinology, Diabetes and …, 2013 - journals.lww.com
The role of combination medical therapy in acromegaly: hope... : Current Opinion in
Endocrinology, Diabetes and Obesity The role of combination medical therapy in …

[HTML][HTML] Extra-hepatic acromegaly

SE Franck, AJ van der Lely, S Neggers - European endocrinology, 2013 - ncbi.nlm.nih.gov
After the introduction of somatostatin analogs (LA-SMSA) and the growth hormone (GH)
receptor antagonist, pegvisomant (Peg-v) normal serum insulin-like growth factor-1 (IGF-1) …

胰岛素联合生长激素上调脓毒症大鼠肝生长激素受体的表达

殷红珍, 虞文魁, 陈启仪, 李宁, 朱维铭, 李维勤, 高涛… - 肠外与肠内营养, 2013 - cqvip.com
目的: 观察脓毒症大鼠在胰岛素联合生长激素治疗前后生长激素受体的变化. 方法: 将56
只造模成功大鼠随机分为七组, 即对照组, 脓毒症组, 胰岛素组, 生长激素组, 联合组, LY294002 …

Influence of pre-analytical conditions on the measurement of components of the GH/IGF axis in rats

M Bielohuby, S Popp, M Bidlingmaier - Growth Hormone & IGF Research, 2013 - Elsevier
Pre-analytical variability characterises effects which are introduced to an analysis by
manipulation and storage of a biological sample after taking it ex-vivo, but before actually …

[PDF][PDF] LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice

JP Salles, B Staels, B Bailleul - researchgate.net
Growth hormone (GH) is a major metabolic regulator that functions by stimulating lipolysis,
preventing protein catabolism, and decreasing insulin-dependent glucose disposal …